Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.
Company profile
Ticker
FLXN
Exchange
Website
CEO
Michael Clayman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Flexion Therapeutics Securities Corporation ...
FLXN stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
29 Nov 21
EFFECT
Notice of effectiveness
26 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
Transcripts
FLXN
Earnings call transcript
2021 Q2
5 Aug 21
FLXN
Earnings call transcript
2021 Q1
13 May 21
FLXN
Earnings call transcript
2020 Q4
11 Mar 21
FLXN
Earnings call transcript
2020 Q1
7 May 20
FLXN
Earnings call transcript
2019 Q4
12 Mar 20
FLXN
Earnings call transcript
2019 Q3
10 Nov 19
FLXN
Earnings call transcript
2019 Q2
6 Aug 19
FLXN
Earnings call transcript
2019 Q1
8 May 19
FLXN
Earnings call transcript
2018 Q4
28 Feb 19
FLXN
Earnings call transcript
2018 Q4
4 Jan 19
Latest ownership filings
SC 13G
Newtyn Management, LLC
24 Nov 21
4
Change in insider ownership
23 Nov 21
3
Initial statement of insider ownership
23 Nov 21
4
Mark Stejbach
19 Nov 21
4
ALAN MILINAZZO
19 Nov 21
4
C ANN MERRIFIELD
19 Nov 21
4
Heath Lukatch
19 Nov 21
4
Elizabeth Kwo
19 Nov 21
4
Utpal Koppikar
19 Nov 21
4
SAMUEL D COLELLA
19 Nov 21
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 136.82 mm | 136.82 mm | 136.82 mm | 136.82 mm | 136.82 mm | 136.82 mm |
Cash burn (monthly) | (no burn) | (no burn) | 10.10 mm | 8.39 mm | 4.74 mm | 5.10 mm |
Cash used (since last report) | n/a | n/a | 311.81 mm | 259.03 mm | 146.12 mm | 157.34 mm |
Cash remaining | n/a | n/a | -174.99 mm | -122.20 mm | -9.30 mm | -20.52 mm |
Runway (months of cash) | n/a | n/a | -17.3 | -14.6 | -2.0 | -4.0 |
Institutional ownership, Q1 2023
2.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 18.14 mm |
Total shares | 1.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Versant Venture Capital III | 1.39 mm | $18.14 mm |